LCRF-AstraZeneca Grant Program
Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 136,000 deaths annually in the United States alone. Despite significant advances in lung cancer treatment, the disease remains the most common cancer killer of both men and women. New treatment modalities such as targeted therapies and immune therapies also pose new and unique challenges. To help address the most profound of these challenges, the 2021 LCRF-AstraZeneca grant program aims to fund innovative projects to:
- Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations
- Develop more effective approaches to address disease progression in patients treated with durvalumab
- Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)
- Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab
Letter of intent due April 30, 2021
1 year
Upper $150,000USD
Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment.
Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics. Ineligible investigators with these or other special circumstances may request review by contacting the LCRF grants office
- Website
Contact
LCRF office
[email protected]